

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
June 25, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the “Company”), Chengdu Suncadia Medicine Co., Ltd. (成都盛迪醫藥有限公司), received a notification from the National Medical Products Administration (hereinafter referred to as the “NMPA”) approving the market launch of the Company’s product, Cyclosporine Ophthalmic Solution (IV). This product is the first and only 0.1% water-free cyclosporine ophthalmic solution in China. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug Name: Cyclosporine Ophthalmic Solution (IV)

Dosage Form: Ophthalmic formulation

Strength: 0.1% (2 mL:2 mg)

Registered Category: Chemical Drug Categories 2.2

Acceptance No.: CXHS2300039

Prescription/Non-prescription Drug: Prescription Drug

Approved Indications: This product promotes tear secretion in patients and is indicated for patients with reduced tear production due to dry eye disease, to improve the signs and symptoms thereof.

II. Other Information of the Drug

The prevalence of dry eye disease in China is about 21.0%–52.4%¹. The guidelines of the International Tear Film & Ocular Surface Society have established that dry eye disease is a condition primarily driven by tear film instability and a vicious cycle of inflammation¹⁻³. Tear hyperosmolarity triggers ocular surface inflammation, leading to corneal damage and tear film instability. An unstable tear film further exacerbates inflammation, and subjective symptoms such as dryness, foreign body sensation, and burning, along with objective signs of damage, ultimately severely impact quality of life and visual function³. Therefore, inhibiting evaporation and anti-inflammatory therapy are important etiological treatments for dry eye disease. However, currently available clinical anti-inflammatory regimens still have many limitations, making it difficult to simultaneously meet the multiple needs of efficacy, safety, and long-term use.

Cyclosporine Ophthalmic Solution (IV) is CyclASol (0.1% cyclosporine A formulation) introduced by the Company from Novaliq GmbH (hereinafter referred to as “Novaliq”). It is a drug developed based on EyeSol®, the world’s first water-free drug delivery technology platform. Compared to water-based 0.05% cyclosporine, Cyclosporine Ophthalmic Solution (IV) has a 17.6-fold increase in bioavailability. It prolongs the drug’s residence time on the cornea while enhancing corneal penetration, allowing it to reach the stromal layer and inhibit T-cell activation and the release of inflammatory cytokines. This protects conjunctival goblet cells, lacrimal gland acinar cells, and corneal epithelial cells, promoting tear secretion and ocular surface repair³⁻⁵. Additionally, the product contains perfluorobutylpentane, a semifluorinated alkane (SFA), which not only serves as the delivery system for cyclosporine but also itself inhibits evaporation, allows oxygen permeation, and promotes corneal repair^{6,7}.

Novaliq’s Cyclosporine Ophthalmic Solution was approved for marketing in the United States in May 2023. According to available data, among other cyclosporine A ophthalmic solutions currently used to treat dry eye disease, Allergan’s Restasis (0.05%, emulsion) and Sun Pharmaceutical’s Cequa (0.09%, nanomicellar aqueous solution) have been approved for marketing in the United States. In China, Xingqi

Pharmaceutical's Category 3 generic drug, Cyclosporine Ophthalmic Solution (II), was approved for marketing by the NMPA in 2020. According to available data, the combined global sales of similar products in 2025 amounted to approximately USD 2.106 billion. As of now, the cumulative research and development investment for Cyclosporine Ophthalmic Solution (IV) related project is approximately RMB 102.6 million (unaudited).

III. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

June 25, 2026

1. Corneal Disease Group, Ophthalmology Division, Chinese Medical Association. Chinese Journal of Ophthalmology, 2024, 60(12):968-976.
2. Corneal Disease Group, Ophthalmology Division, Chinese Medical Association. Chinese Journal of Ophthalmology, 2013, 49(1):73-75.
3. Stapleton F, et al. TFOS DEWS III: Digest. Am J Ophthalmol. 2025;279:451-553.
4. Agarwal P, et al. Int J Pharm. 2018;538(1-2):119-129
5. Agarwal P, et al. EVER 2016.
6. Agarwal P, et al. Expert Opin Drug Deliv. 2025;22(9):1359-1374.
7. Peng R, et al. JAMA Ophthalmol. 2024 Apr 1;142(4):337-343.